- Missouri voters oppose prescription-only restrictions on PSE
- On the heels of Q3, Walgreens outlines shift in front-end strategy and pharmacy tailwinds looking forward
- Kathleen Sebelius cites pharmacists' importance as Rite Aid CEO introduces Obamacare resource program
- New Rite Aid group VP pharmacy initiatives and clinical services to oversee Wellness Ambassador program
- Pain Relief 2013
MORRISTOWN, N.J. — Over-the-counter generic versions of a line of products used to treat congestion do not infringe on the patents covering the branded versions, a federal court ruled Wednesday.
Watson Pharmaceuticals said the U.S. District Court for the Southern District of Florida ruled that its versions of Reckitt Benckiser’s Mucinex (guaifenesin), Mucinex D (guaifenesin and dextromethorphan-hydrobromide) and Mucinex DM (guaifenesin and pseudoephedrine) do not infringe U.S. Patent No. 6,372,252. Watson still is seeking Food and Drug Administration approval for its version.
Mucinex is used to loosen phlegm and clear the bronchial passageways. The product line had sales of about $500 million in 2010, according to IMS Health and SymphonyIRI.